INVITRO METABOLISM OF 3-(1-HYDROXY-2-PIPERIDINOETHYL)-5-PHENYLISOXAZOLE CITRATE (31252-S) WITH RABBIT LIVER HOMOGENATE

被引：0
|
作者：
HASHIMOTO, SI [1 ]
SHIZU, M [1 ]
TAKAHASHI, S [1 ]
机构：
[1] SHIONOGI & CO LTD, SHIONOGI RES LAB, FUKUSHIMA KU, OSAKA 553, JAPAN
来源：
CHEMICAL & PHARMACEUTICAL BULLETIN | 1976年 / 24卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
引用
收藏
页码：1757 / 1764
页数：8
相关论文
共 41 条
  • [31] Synthesis and Pharmacological Characterization of 2-(2,6-Dichlorophenyl)-1((1S,3R)-5-(3-hydroxy-3-methylbutyl)-3-(hydroxymethyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one (LY3154207), a Potent, Subtype Selective, and Orally Available Positive Allosteric Modulator of the Human Dopamine D1 Receptor
    Hao, Junliang
    Beck, James P.
    Schaus, John M.
    Krushinski, Joseph H.
    Chen, Qi
    Beadle, Christopher D.
    Vidal, Paloma
    Reinhard, Matthew R.
    Dressman, Bruce A.
    Massey, Steven M.
    Boulet, Serge L.
    Cohen, Michael P.
    Watson, Brian M.
    Tupper, David
    Gardiner, Kevin M.
    Myers, Jason
    Johansson, Anette M.
    Richardson, Jeffery
    Richards, Daniel S.
    Hembre, Erik J.
    Remick, David M.
    Coates, David A.
    Bhardwaj, Rajni M.
    Diseroad, Benjamin A.
    Bender, David
    Stephenson, Greg
    Wolfangel, Craig D.
    Diaz, Nuria
    Getman, Brian G.
    Wang, Xu-shan
    Heinz, Beverly A.
    Cramer, Jeff W.
    Zhou, Xin
    Maren, Deanna L.
    Falcone, Julie F.
    Wright, Rebecca A.
    Mitchell, Stephen N.
    Carter, Guy
    Yang, Charles R.
    Bruns, Robert F.
    Svensson, Kjell A.
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (19) : 8711 - 8732
  • [32] Design and synthesis of highly potent benzodiazepine γ-secretase inhibitors:: Preparation of (2S,3R)-3-(3,4-difluorophenyl)-2-(4-fluorophenyl)-4-hydroxy-N-((3S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]- diazepin-3-yl)butyramide by use of an asymmetric Ireland-Claisen rearrangement
    Churcher, I
    Williams, S
    Kerrad, S
    Harrison, T
    Castro, JL
    Shearman, MS
    Lewis, HD
    Clarke, EE
    Wrigley, JDJ
    Beher, D
    Tang, YS
    Liu, WS
    JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (12) : 2275 - 2278
  • [33] (1R*, 5R*, 7R*, 8S*)-3-(3,4-dihydroxybenzoyl)-4-hydroxy-8-methyl-1,5,7-tris(3-methyl-2-butenyl)-8-(4-methyl-3-pentenyl)bicyclo[3.3.1]non-3-ene-2,9-dione
    Lenta, Bruno Ndjakou
    Noungoue, Diderot Tchamo
    Devkota, Krishna Prasad
    Fokou, Patrice Aime
    Ngouela, Silvere
    Etienne, Tsamo
    Sewald, Norbert
    ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS, 2007, 63 : o1282 - o1284
  • [34] Tetraphenylborate Salt of Atropine®: Synthesis and X-ray Structure of Tetraphenyl-λ4-borane, (1R,3r,5S,8s)-3-((3-Hydroxy-2-phenylpropanoyl)oxy)-8-methyl-8-azabicyclo[3.2.1]octan-8-ium Salt
    G. A. E. Mostafa
    H. A. Ghabbour
    H. A. Abdel-Aziz
    Crystallography Reports, 2017, 62 : 1083 - 1088
  • [35] Tetraphenylborate Salt of Atropine®: Synthesis and X-ray Structure of Tetraphenyl-λ4-borane, (1R,3r,5S,8s)-3-((3-Hydroxy-2-phenylpropanoyl)oxy)-8-methyl-8-azabicyclo[3.2.1]octan-8-ium Salt
    Mostafa, G. A. E.
    Ghabbour, H. A.
    Abdel-Aziz, H. A.
    CRYSTALLOGRAPHY REPORTS, 2017, 62 (07) : 1083 - 1088
  • [36] Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist
    Serradeil-Le Gal, C
    Wagnon, J
    Simiand, J
    Griebel, G
    Lacour, C
    Guillon, G
    Barberis, C
    Brossard, G
    Soubrié, P
    Nisato, D
    Pascal, M
    Pruss, R
    Scatton, B
    Maffrand, JP
    Le Fur, G
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 300 (03): : 1122 - 1130
  • [37] MODIFIED METABOLISM OF A CARCINOGEN, 3-AMINO-1-METHYL-5H-PYRIDO[4,3-B]INDOLE (TRP-P-2), BY LIVER S9 FROM SCHISTOSOMA-JAPONICUM-INFECTED MICE
    ARIMOTO, S
    MATSUOKA, H
    AJI, T
    ISHII, A
    WATAYA, Y
    HAYATSU, H
    MUTATION RESEARCH, 1992, 282 (03): : 177 - 182
  • [38] In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes:: Involvement of cytochromes P450 in atypical kinetics and potential drug interactions
    Tachibana, S
    Fujimaki, Y
    Yokoyama, H
    Okazaki, O
    Sudo, K
    DRUG METABOLISM AND DISPOSITION, 2005, 33 (11) : 1628 - 1636
  • [39] Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate (S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385)
    Wehn, Paul M.
    Rizzi, James P.
    Dixon, Darryl D.
    Grina, Jonas A.
    Schlachter, Stephen T.
    Wang, Bin
    Xu, Rui
    Yang, Hanbiao
    Du, Xinlin
    Han, Guangzhou
    Wang, Keshi
    Cao, Zhaodan
    Cheng, Tzuling
    Czerwinski, Robert M.
    Goggin, Barry S.
    Huang, Heli
    Halfmann, Megan M.
    Maddie, Melissa A.
    Morton, Emily L.
    Olive, Sarah R.
    Tan, Huiling
    Xie, Shanhai
    Wong, Tai
    Josey, John A.
    Wallace, Eli M.
    JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (21) : 9691 - 9721
  • [40] Crystal structure of (1S,3S,6S,7S,8S,9R)-7-acetoxy-9-hydroxy 6-(4-methoxybenzyl)-3-[N-methyl-N-(4-methylphenyl)sulfonylamino]-5-azatricyclo[6.3.1.01.5]dodecan-4-one, C29H36N2O7S
    Ousmer, M
    Braun, NA
    Ciufolini, MA
    Perrin, M
    ZEITSCHRIFT FUR KRISTALLOGRAPHIE-NEW CRYSTAL STRUCTURES, 2000, 215 (04): : 597 - 599
12345